Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: A pharmacokinetic and bioequivalence study

Pediatric Nephrology

Volumn 29, Issue 6, 2014, Pages 1081-1088

  Lapeyraque, Anne Laure ^a   Kassir, Nastya ^b   Théorêt, Yves ^a   Krajinovic, Maja ^a   Clermont, Marie José ^a   Litalien, Catherine ^a   Phan, Véronique ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Pediatric kidney transplantation; Pharmacogenetic; Pharmacokinetic; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHILD; CLINICAL ARTICLE; DRUG FORMULATION; FEMALE; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PEDIATRIC SURGERY; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ADOLESCENT; CLINICAL TRIAL; GENETICS; GRAFT REJECTION; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

ADOLESCENT; AREA UNDER CURVE; CHILD; CYTOCHROME P-450 CYP3A; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PHARMACOGENETICS; TACROLIMUS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84901641731     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2724-0     Document Type: Article

References (52)

1. Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN (2010) Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant 14:603-613
2. Shellmer DA, Dabbs AD, Dew MA (2011) Medical adherence in pediatric organ transplantation: what are the next steps? Curr Opin Organ Transplant 16:509-514
3. Fredericks EM, Dore-Stites D (2010) Adherence to immunosuppressants: how can it be improved in adolescent organ transplant recipients? Curr Opin Organ Transplant 15:614-620
4. Weng FL, Israni AK, Joffe MM, Hoy T, Gaughan CA, Newman M, Abrams JD, Kamoun M, Rosas SE, Mange KC, Strom BL, Brayman KL, Feldman HI (2005) Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 16:1839-1848
5. Shemesh E, Shneider BL, Savitzky JK, Arnott L, Gondolesi GE, Krieger NR, Kerkar N, Magid MS, Stuber ML, Schmeidler J, Yehuda R, Emre S (2004) Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 113:825-832
6. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC (2009) Effect of medication dosing frequency on adherence in chronic diseases. Am J Manage Care 15:e22-e33
7. Robles-Piedras AL, Gonzalez-Lopez EH (2009) Tacrolimus levels in adult patients with renal transplant. Proc West Pharmacol Soc 52:33-34
8. Claeys T, Van Dyck M, Van Damme-Lombaerts R (2010) Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. Pediatr Nephrol 25:335-342
9. Lee MN, Butani L (2007) Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant 11:388-393
10. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE (2011) Once-versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 71:1561-1577
11. Hougardy JM, de Jonge H, Kuypers D, Abramowicz D (2012) The once-daily formulation of tacrolimus: a step forward in kidney transplantation? Transplantation 93:241-243
12. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y (2010) Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 90:523-529
13. Wu MJ, Cheng CY, Chen CH, Wu WP, Cheng CH, Yu DM, Chuang YW, Shu KH (2011) Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation 92:648-652
14. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le Moine A, Hoang AD, Mikhalski D, Wissing KM, Abramowicz D (2011) Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 91:566-569
15. Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Guri X, Rap O, Moral R, Puig JM, Lloveras J (2009) De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 41:2115-2117
16. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254
17. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706-2713
18. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74: 1486-1489
19. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T (2004) Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78:1182-1187
20. Macphee IA (2010) Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit 32:261-264
21. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711-725
22. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483
23. Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M (2012) Comparison of pharmacokinetics and pharmacogenetics of once-and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 94: 1013-1019
24. Bourgeois S, Labuda D (2004) Dynamic allele-specific oligonucleotide hybridization on solid support. Anal Biochem 324:309-311
25. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024-2027
26. Foster BJ, Dahhou M, Zhang X, Platt RW, Samuel SM, Hanley JA (2011) Association between age and graft failure rates in young kidney transplant recipients. Transplantation 92:1237-1243
27. Pape L, Heidotting N, Ahlenstiel T (2011) Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. Int J Nephrol 2011:126251
28. Hatakeyama S, Fujita T, Yoneyama T, Koie T, Hashimoto Y, Saitoh H, Funyu T, Narumi S, Ohyama C (2012) A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. Transplant Proc 44:121-123
29. Tinti F, Mecule A, Poli L, Bachetoni A, Umbro I, Brunini F, Barile M, Nofroni I, Berloco PB, Mitterhofer AP (2010) Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc 42:4047-4048
30. Abdulnour HA, Araya CE, Dharnidharka VR (2010) Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 14:1007-1011
31. Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, Vanrenterghem Y, Kramer BK, Abramowicz D, Oppenheimer F, Pietruck F, Russ G, Karpf C, Undre N (2009) Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 9:2505-2513
32. Wlodarczyk Z, Ostrowski M, Mourad M, Kramer BK, Abramowicz D, Oppenheimer F, Miller D, Dickinson J, Undre N (2012) Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial. Ther Drug Monit 34:143-147
33. Fischer L, Trunecka P, Gridelli B, Roy A, Vitale A, Valdivieso A, Varo E, Seehofer D, Lynch S, Samuel D, Ericzon BG, Boudjema K, Karpf C, Undre N (2011) Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl 17:167-177
34. Tang HL, Xie HG, Yao Y, Hu YF (2011) Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 21:713-720
35. Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, Numakura K, Tsuchiya N, Tada H, Suzuki T, Habuchi T (2008) Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol 66:207-214
36. Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, Habuchi T (2011) Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12:977-984
37. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N (2011) Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 28:1093-1102
38. van Hooff J, Van der Walt I, Kallmeyer J, Miller D, Dawood S, Moosa MR, Christiaans M, Karpf C, Undre N (2012) Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 34:46-52
39. Tirelli S, Ferraresso M, Ghio L, Meregalli E, Martina V, Belingheri M, Mattiello C, Torresani E, Edefonti A (2008) The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Med Sci Monit 14:CR251-CR254
40. Wang P, Mao Y, Razo J, Zhou X, Wong ST, Patel S, Elliott E, Shea E, Wu AH, Gaber AO (2010) Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 11:1389-1402
41. Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, Campbell SB, Leary DR, Staatz CE (2011) Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 71:207-223
42. Mecule A, Poli L, Nofroni I, Bachetoni A, Tinti F, Umbro I, Barile M, Berloco PB, Mitterhofer AP (2010) Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 42:1317-1319
43. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR (2007) Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 83: 1648-1651
44. Kramer BK, Charpentier B, Backman L, Silva HT Jr, Mondragon-Ramirez G, Cassuto-Viguier E, Mourad G, Sola R, Rigotti P, Mirete JO, Tacrolimus Prolonged Release Renal Study G (2010) Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 10:2632-2643
45. Christians U, Klawitter J, Clavijo CF (2010) Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl:S1-7
46. Karalis V, Macheras P (2012) Current regulatory approaches of bioequivalence testing. Expert Opin Drug Metab Toxicol 8:929-942
47. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA (2011) Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 72:948-957
48. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-653
49. Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, Lorkowski C, Slowinski T, Neumayer HH, Budde K (2011) Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 21:179-184
50. Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP (2007) Expression of CYP3A isoforms and Pglycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 34:1138-1144
51. Canaparo R, Nordmark A, Finnstrom N, Lundgren S, Seidegard J, Jeppsson B, Edwards RJ, Boobis AR, Rane A (2007) Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin Pharmacol Toxicol 100:240-248
52. Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provot F, Hazzan M, Noel C, Broly F, Cauffiez C (2011) CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant 26:3046-3050